Centralized and point-of-care division sales contributed most to the revenue growth, and were spurred on by a 13 percent lift in immunodiagnostics revenues.
The Liat point of care system system has launched with four assays, including three respiratory tests and a novel test for Clostridium difficile.
The test for cervical cancer screening previously received the IVD mark and US Food and Drug Administration approval on the Cobas 4800 system.
The companies are aiming to develop and commercialize a test to identify patients likely to respond to Loxo's cancer drug larotrectinib.
Mutation and predicted neoantigen profiles for more than 63,000 tumors suggests it would be difficult to design a broadly beneficial cancer vaccine.
The study compared five methods, including three based on Roche test kits and reagents, and suggested that a multiplexed test may be best to avoid false-negative results.
MDx product sales for diagnosing and monitoring hepatitis and HIV load, and screening HPV, grew 7 percent year over year.
Companies with diverse infectious disease diagnostic technology offerings said that molecular methods are complementary to, not competitive with traditional diagnostics.
It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.
The university claims that Genia's patents are based on technology that was developed by UCSC researchers and that UCSC should have ownership of them.
York University researchers find genomic evidence of inbreeding in the yellow-banded bumblebee, according to Reuters.
In its survey of US adults, the Pew Research Center finds that views on the genetic engineering of animals depend on why it's done.
The Scientist reports agricultural researchers are working on a gene-stacking tool.
In Nature this week: statistical method for overcoming case-control imbalance issues, and more.